when

Latest
Archive

by source

All Sources
Sources Page

department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Jobs
News

Hubs

Topics
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
search

pharmadog news

Browse

2,094 stories matching this filter · ← front page

★ save view ↓export CSV

rangeto

sort

recent oldest source alpha

source

STAT1220 Endpoints923 BioPharma Dive355 BioSpace342 Fierce Biotech325 onclive165 raps111 globenewswire health

therapy area

all Oncology8305 Rare Disease1946 Cardiology1880 Immunology1591 Hematology1354 Pulmonology1298 Vaccines

The signal that changes everything: understanding MRD in oncology drug development
Is the cancer truly gone?
Fierce Biotech · 3d ago↗ source
Novo Nordisk halts two IL-6 heart trials as Novartis suffers Phase 3 setbacks; Ionis wins first Alexander disease approval
Novo Nordisk announced it has ended two late‑stage studies of its investigational IL‑6 inhibitor ziltivekimab, which was being evaluated for cardiovascular disease. The decision follows an earlier…
BioSpace · 5d agoNegative↗ source
Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail

page 4 of 84

73

1283

Psychiatry & CNS899

Ophthalmology521

Endocrinology & Metabolism497

Infectious Disease461

Evommune’s MRGPRX2 antagonist has flunked another phase 2 trial, wiping out the biotech’s last hopes of developing the therapy for any itch-related conditions.

Fierce Biotech · 5d agoNegative readoutNegative↗ source

Sandoz to invest $1 billion in European biosimilar hub, targeting 100 biosimilars by 2040

Sandoz announced at its investor day that it will spend roughly $1 billion to build a fully integrated European biosimilar hub as part of a plan to bring more than 100 biosimilars to market by 2040…

BioSpace · 5d agoPositive↗ source

Solstice Oncology secures $225M Series A to launch FDA-cleared Phase 2 CTLA-4 antibody trial

Solstice Oncology, a cancer-focused startup that emerged from stealth in February, announced a $225 million Series A financing round to fund its early-stage programs. The capital will be used to a…

BioSpace · 5d agoDealPositive↗ source

Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancer

Solstice Oncology, a biotech startup focused on immunotherapy, announced it has raised $225 million in a Series A financing round. The funding will support development of its lead candidate, a CTL…

BioPharma Dive · 5d agoDealPositive↗ source

Luma Group closes $410 million, 15-year life-science venture fund

Luma Group announced that its first life‑science venture capital fund has reached final close, raising $410 million for a 15‑year investment period. The New York‑based firm said the capital will be…

Fierce Biotech · 5d agoDealPositive↗ source

Encoded Therapeutics secures $275M Series F to push Dravet gene therapy and expand manufacturing

Encoded Therapeutics, a biotech focused on neuro‑genetic disorders, announced a $275 million Series F financing round. The capital was co‑led by Google Ventures and an undisclosed healthcare fund,…

Fierce Biotech · 5d agoDealPositive↗ source

Tyra Biosciences reports phase 2 bladder cancer data, complete response rates miss analyst targets, shares slide

Tyra Biosciences disclosed early phase 2 results for its FGFR3‑selective inhibitor dabogratinib in patients with low‑grade, intermediate‑risk non‑muscle‑invasive bladder cancer. The trial evaluate…

Fierce Biotech · 5d agoNegative readoutNegative↗ source

Abbott receives FDA clearance for TactiFlex Duo catheter, offering flexible AFib ablation options

Abbott announced that the U.S. Food and Drug Administration has cleared its new TactiFlex Duo catheter for use in atrial fibrillation ablation. The catheter can deliver pulsed field ablation, radi…

Fierce Biotech · 5d agoRegulatoryPositive↗ source

Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3

Beeline Medicines announced that its oral small-molecule inhibitor afimetoran achieved the primary endpoint in a 48-week Phase 2 trial in patients with systemic lupus erythematosus (SLE). The tria…

Fierce Biotech · 5d agoPositive readoutPositive↗ source

Tyra Biosciences’ bladder cancer pill misses expected response rate in Phase 2 trial

Shares of Tyra Biosciences dropped about 20% after data from its Phase 2 study of a bladder cancer pill fell short of market expectations. The experimental drug, dabogratinib, is taken daily and t…

BioPharma Dive · 4d agoNegative readoutNegative↗ source

Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome program

Encoded Therapeutics announced closing a Series F financing round that brought in $275 million. The round was led by GV with participation from an undisclosed healthcare investor. The new capital…

Endpoints · 4d agoDealPositive↗ source

Kura Oncology launches Caspian Therapeutics to develop menin-inhibitor diabetes drug with $50M funding

Kura Oncology has spun out a new biotech called Caspian Therapeutics to focus on menin inhibitors for diabetes and other cardiometabolic diseases. The company’s lead candidate, code-named KO-7246,…

BioPharma Dive · 4d agoDealPositive↗ source

Research on orexin and narcolepsy earns Lasker Award for Yanagisawa and Mignot

Masashi Yanagisawa and Emmanuel Mignot were honored with the Lasker Award for their work uncovering the role of orexin in narcolepsy. The award was announced on September 9, 2026. Their research b…

Endpoints · 4d agoPositive↗ source

Compass Pathways reports positive one-year data for its psilocybin therapy COMP360

Compass Pathways released results from a one-year study of its psilocybin‑based therapy COMP360. The company described the data as positive, indicating continued promise for the investigational tre…

Endpoints · 4d agoPositive readoutPositive↗ source

FDA appoints permanent heads of CDER and CBER, adding AI deputy role

The Trump administration announced permanent appointments to two key FDA centers after a period of turnover. Michael Davis, who had been acting director of the Center for Drug Evaluation and Resea…

BioPharma Dive · 4d agoRegulatoryPositive↗ source

Webinar explores how GLP-1 obesity drugs are reshaping US healthcare and market dynamics

The upcoming webinar titled "The Massive Scale of GLP-1s: Evolving Health, Healthcare and Markets" will examine how GLP-1 receptor agonists used for obesity are altering the U.S. health-care landsc…

BioSpace · 4d agoNeutral↗ source

nPhase unveils AI-driven clinical data platform to accelerate trial design and submission

nPhase, a clinical research organization, announced the launch of an end-to-end platform called nPhase.ai that uses artificial intelligence to manage clinical trial data. The platform includes a S…

Fierce Biotech · 4d agoPositive↗ source

BMS reports positive mid-stage results for arlo-cel in heavily pre-treated myeloma patients

BMS said its CAR T therapy arlo-cel, formally arlocabtagene autoleucel, achieved positive results in a registrational mid-stage study for relapsed and refractory multiple myeloma. The open-label,…

BioSpace · 5d agoPositive readoutPositive↗ source

TwoStep Therapeutics raises $62.5 million Series A backed by Pfizer and Merck KGaA venture groups

TwoStep Therapeutics, a cancer biotech, announced a $62.5 million Series A financing to advance its novel approach to antibody-drug conjugates and radioligand therapies. The round was supported by…

Endpoints · 5d agoDealPositive↗ source

Kura Oncology spins out diabetes program into new company with $50M funding and Lilly support

Kura Oncology, known for its leukemia menin inhibitor Komzifti, announced it is separating its diabetes research into a newly formed company. The new entity will receive $50 million in financing,…

Endpoints · 5d agoDealPositive↗ source

Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trial

Tyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study. The company said the data, released on Wednesday, represen…

Endpoints · 5d agoPositive readoutPositive↗ source

Caspian Therapeutics launches with $50M funding and Eli Lilly backing to develop menin inhibitor for diabetes

Caspian Therapeutics has been created as a spin-out from Kura Oncology to advance a menin-targeting drug for diabetes. The company received $50 million in initial capital, led by BVF Partners with…

BioSpace · 5d agoDealPositive↗ source

Kura Oncology launches Caspian Therapeutics with $50M funding to develop next-generation diabetes drug

Kura Oncology has created a new biotech called Caspian Therapeutics and secured $50 million in financing to advance a next-generation diabetes treatment. The spinout will focus on KO-7246, a highl…

Fierce Biotech · 5d agoDealPositive↗ source